India to Yemen: Torsemide Export Trade Route

The India to Yemen Torsemide corridor is one of India's established pharmaceutical export routes, with 25 shipments documented worth a combined $545.2K USD. The route is dominated by CIPLA LIMITED, which alone accounts for roughly 88% of all export value, reflecting the consolidated nature of India's torsemide manufacturing sector.

Across 7 active suppliers, the average shipment value stands at $21.8K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 74% of all shipments, consistent with torsemide's non-urgent bulk-order profile.

Shipment activity peaks during October–December, with an average transit time of 21 days port-to-port. The route has recorded an annual growth rate of 28.5%, placing it at rank #1 among India's top torsemide export destinations globally.

On the import side, key buyers of Indian torsemide in Yemen include CIPLAMEDICA PHARMACEUTICAL INDUSTRI, MEDICA PHARMACEUTICAL INDUSTRIES L, TO THE ORDER OF ALKURAIMI ISLAMIC and 7 others. CIPLAMEDICA PHARMACEUTICAL INDUSTRI is the single largest importer with 12 shipments valued at $383.3K USD.

India's torsemide exports to Yemen are driven primarily by a handful of large-scale manufacturers. CIPLA LIMITED with 15 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 7 active exporters signals a competitive but concentrated market — buyers in Yemen benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — CIPLA LIMITED, SCOTT EDIL PHARMACIA LIMITED, MASCOT HEALTH SERIES PRIVATE LIMITED. — together account for 99% of total trade value on this route. The average shipment value of $21.8K USD reflects a mix of bulk commercial orders and smaller specialty shipments.

Beyond the primary product category, shipments on this route include closely related formulations such as dytor 20 mg tablets torsemide tablets20 mg inv.qty.9643 pack 10x10s=964300nos and dytor 20 mg tablets torsemide tablets20 mg inv.qty.9828 pack 10 x 10s =982800 nos, suggesting that buyers in Yemen tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, CIPLAMEDICA PHARMACEUTICAL INDUSTRI is the largest importer with 12 shipments worth $383.3K USD — representing 70% of all torsemide imports from India on this route. A total of 10 buyers are active on this corridor.